Synfini Adds $8.9 Million Discovery Funding to Speed Small Molecule Drug Development

MENLO PARK, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Synfini, Inc., a trailblazer in AI-driven chemistry automation, today announced a $8.9 million expansion of its round, led by JSL Health Capital and supported by a strong syndicate of early-stage investors. This brings Synfini's total funding to $53 million, comprised of non-dilutive grants and venture investment. The company's AI Cloud Foundry platform uniquely integrates artificial intelligence, automated synthesis, and iterative molecular design to dramatically accelerate small molecule drug discovery and synthesis. By combining physical and virtual chemistry in a unified workflow, Synfini delivers novel, high-quality pharmaceutically optimized compounds at unprecedented speed, while dramatically reducing costs. 

Synfini's platform eliminates traditional bottlenecks in early drug discovery by streamlining target selection, compound design, and synthesis into an agile, integrated workflow, replacing traditional manual chemistry processes. Since its spinout from SRI in 2023, the company has validated its approach through early ...